Menu Back toLS34: Impact of COVID-19 on US Clinical Studies Conducted by Japan-Based Pharmaceutical Companies

18th DIA Japan Annual Meeting 2021

All prices are exclusive of 10% Japanese consumption tax

LS34: Impact of COVID-19 on US Clinical Studies Conducted by Japan-Based Pharmaceutical Companies

Session Chair(s)

Kazumi  Taguchi

Kazumi Taguchi

  • Director
  • SOCIUM Inc., Japan

Speaker(s)

Yu  Tanaka

Yu Tanaka

  • Project Manager
  • Project Planning & Management Forum NY Chapter, United States
Takahiro  Yoshida

Takahiro Yoshida

  • Senior Specialist Clinical Research
  • MSD K.K., Japan
Masaya  Tanaka

Masaya Tanaka

  • Director, Clinical Operations
  • ONO PHARMACEUTICAL CO., LTD., United States

Contact us